# The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy

> **NCT03517501** · PHASE3 · WITHDRAWN · sponsor: **Asahi Kasei Pharma America Corporation**

## Conditions studied

- Sepsis and Coagulopathy

## Interventions

- **DRUG:** ART-123
- **DRUG:** Placebo Comparator - Placebo

## Key facts

- **NCT ID:** NCT03517501
- **Lead sponsor:** Asahi Kasei Pharma America Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-07
- **Primary completion:** 2022-04
- **Final completion:** 2023-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor will amend study design by incorporating reconfirmation of coagulopathy following discussion with FDA regarding findings from SCARLET1 study.
- **Last updated:** 2019-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03517501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03517501, "The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03517501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*